Nature Communications (Jul 2023)

Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer

  • Zhe Jiang,
  • YoungJun Ju,
  • Amjad Ali,
  • Philip E. D. Chung,
  • Patryk Skowron,
  • Dong-Yu Wang,
  • Mariusz Shrestha,
  • Huiqin Li,
  • Jeff C. Liu,
  • Ioulia Vorobieva,
  • Ronak Ghanbari-Azarnier,
  • Ethel Mwewa,
  • Marianne Koritzinsky,
  • Yaacov Ben-David,
  • James R. Woodgett,
  • Charles M. Perou,
  • Adam Dupuy,
  • Gary D. Bader,
  • Sean E. Egan,
  • Michael D. Taylor,
  • Eldad Zacksenhaus

DOI
https://doi.org/10.1038/s41467-023-39935-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Metastatic breast-cancer is a major cause of death in women worldwide, yet the relationship between oncogenic drivers that promote metastatic versus primary cancer is still contentious. To elucidate this relationship in treatment-naive animals, we hereby describe mammary-specific transposon-mutagenesis screens in female mice together with loss-of-function Rb, which is frequently inactivated in breast-cancer. We report gene-centric common insertion-sites (gCIS) that are enriched in primary-tumors, in metastases or shared by both compartments. Shared-gCIS comprise a major MET-RAS network, whereas metastasis-gCIS form three additional hubs: Rho-signaling, Ubiquitination and RNA-processing. Pathway analysis of four clinical cohorts with paired primary-tumors and metastases reveals similar organization in human breast-cancer with subtype-specific shared-drivers (e.g. RB1-loss, TP53-loss, high MET, RAS, ER), primary-enriched (EGFR, TGFβ and STAT3) and metastasis-enriched (RHO, PI3K) oncogenic signaling. Inhibitors of RB1-deficiency or MET plus RHO-signaling cooperate to block cell migration and drive tumor cell-death. Thus, targeting shared- and metastasis- but not primary-enriched derivers offers a rational avenue to prevent metastatic breast-cancer.